326 related articles for article (PubMed ID: 15605761)
21. Lymph-node-negative oestrogen-receptor-positive breast cancer.
Pansegrau GK; Gelmon KA
Lancet; 2004 Sep 4-10; 364(9437):820-1. PubMed ID: 15351171
[No Abstract] [Full Text] [Related]
22. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen: an enduring star.
Veronesi U; Maisonneuve P; Decensi A
J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
[No Abstract] [Full Text] [Related]
24. Tamoxifen in early breast cancer.
Bryce CJ
Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952
[No Abstract] [Full Text] [Related]
25. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.
Jordan VC; Lewis JS; Osipo C; Cheng D
Breast; 2005 Dec; 14(6):624-30. PubMed ID: 16202599
[TBL] [Abstract][Full Text] [Related]
26. Endocrine therapy for breast cancer: an overview.
Cheung KL
Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
[TBL] [Abstract][Full Text] [Related]
27. Should you be taking tamoxifen?
Johns Hopkins Med Lett Health After 50; 2001 Jun; 13(4):4-5. PubMed ID: 11439691
[No Abstract] [Full Text] [Related]
28. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
Muss HB; Bunn JY; Crocker A; Plaut K; Koh J; Heintz N; Rincon M; Weaver DL; Tam D; Beatty B; Kaufman P; Donovan M; Verbel D; Weiss L
Breast J; 2007; 13(4):337-45. PubMed ID: 17593037
[TBL] [Abstract][Full Text] [Related]
29. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
30. [Action of SERM and SAS (tibolone) on breast tissue].
Gompel A; Jacob D; de Chambine S; Mimoun M; Decroix Y; Rostene W; Poitout P
Contracept Fertil Sex; 1999 May; 27(5):368-75. PubMed ID: 10401183
[TBL] [Abstract][Full Text] [Related]
31. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
32. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
34. Chemoprevention of breast cancer for women at high risk.
Chan K; Morris GJ
Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
[TBL] [Abstract][Full Text] [Related]
35. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer.
Dimitrov NV; Colucci P; Nagpal S
Oncologist; 2007 Jul; 12(7):798-807. PubMed ID: 17673611
[TBL] [Abstract][Full Text] [Related]
36. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
[TBL] [Abstract][Full Text] [Related]
38. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
[TBL] [Abstract][Full Text] [Related]
40. Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.
Hanstein B; Djahansouzi S; Dall P; Beckmann MW; Bender HG
Eur J Endocrinol; 2004 Mar; 150(3):243-55. PubMed ID: 15012607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
